Cent Raises $5M for AI Disease Detection

Cent's approach integrates advanced imaging like whole-body MRIs and low-dose CT scans with over 120 biomarkers from blood and urine tests. This comprehensive data is then analyzed by AI to screen for more than 300 potential health conditions in a single visit, generating organ-level risk assessments. The startup's proprietary protocol is called CCNM, focusing on Cardiac, Cancer, Neurological, and Metabolic health. The founding team, led by Practo's Shashank ND, includes former Lenskart executive Arpit Garg and ex-Ola Electric leader Anshul Khandelwal, bringing together experience in healthcare platforms, AI, and consumer technology. The venture was personally motivated after Shashank lost three family members to late-stage cancer in 2024, highlighting the need for earlier detection before symptoms appear. Cent is pursuing a direct-to-consumer model, with revenue coming directly from patients rather than through insurers or hospitals. For consumer health apps, building trust is paramount and can be achieved by publishing research, transparently communicating about security and compliance, and forming strategic partnerships with established healthcare institutions. Successful apps like Headspace and Flo have leveraged this by focusing on retention and demonstrating value before pushing for monetization. Headspace utilized a content-led SEO strategy and partnerships with companies like Spotify to build a trusted brand, while Flo's detailed, multi-screen onboarding process builds user confidence by explaining the "why" behind data collection. Integrating with wearables is a key growth vector, with unified APIs now allowing apps to connect with Apple HealthKit, Fitbit, Oura, and Whoop through a single integration, significantly cutting development time. This allows for the aggregation of diverse health data points, from heart rate variability to sleep patterns, enabling the AI-driven personalization that users now expect. However, this data often falls outside of HIPAA's scope, making compliance with state privacy laws and the FTC's Health Breach Notification Rule critical for maintaining user trust. The longevity and biohacking space offers a glimpse into the future of proactive health, with startups like Altos Labs and BioAge Labs targeting the underlying mechanisms of aging. These companies focus on concepts like "partial epigenetic reprogramming" to restore cellular resilience. While many of these therapies are still in early stages, the movement highlights a consumer desire to extend "healthspan," not just lifespan, a trend that aligns with the preventative goals of platforms like Cent. AI is becoming central to personalizing medicine, with algorithms analyzing genomic data to predict medication responses and improve diagnostic accuracy by as much as 38% in some cancer treatments. This shift allows for proactive interventions based on an individual's unique genetic and lifestyle data, moving away from a one-size-fits-all approach. AI-powered tools can identify subtle patterns in health data that might otherwise be missed, enabling earlier risk detection for conditions like diabetes and cardiovascular disease. Early-stage digital health fundraising remains robust, with AI-driven companies attracting significant investment. Venture funds like Rock Health, Khosla Ventures, and Founders Fund are actively investing in startups that demonstrate strong clinical evidence and a clear path to improving healthcare accessibility and quality. For founders transitioning from a technical role to CEO, a key challenge is articulating a compelling vision that resonates with both investors and health-conscious consumers, often by grounding the company's mission in a relatable, human story.